Article

Impact of <i>BRCA</i> mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapy

2020-09-28

Abstract excerpt

<h4>Introduction</h4> Five to 10% of breast cancers (BCs) occur in a genetic predisposition context (mainly BRCA pathogenic variant). Nevertheless, little is known about immune tumor infiltration, response to neoadjuvant chemotherapy (NAC), pathologic complete response (pCR) and adverse events according to BRCA status. <h4>Material and methods</h4> Out of 1199 invasive BC patients treated with NAC between 2002 and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 93eba7a4-d4bf-5b75-aebb-d29f0f1c6656
DOI: 10.1101/2020.09.27.20202515

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Impact of <i>BRCA</i> mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapyDOI 10.1101/2020.09.27.20202515Read

The Molecular Landscape of Asian Breast Cancers Reveals Clinically Relevant Population-Specific DifferencesSemantic proximity Read

Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancerSemantic proximity Read

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.Semantic proximity Read

Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: A meta-analysisSemantic proximity Read

Triple Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant ChemotherapySemantic proximity Read

Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.Semantic proximity Read

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.Semantic proximity Read

Tumor-Infiltrating Lymphocytes Display Prognostic Signatures Associated with Chemotherapy Response in TNBC PatientsSemantic proximity Read

Breast cancer genomics and immuno-oncological markers to guide immune therapiesSemantic proximity Read

Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: A systematic review and meta-analysisSemantic proximity Read

Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapySemantic proximity Read

Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune SuppressionSemantic proximity Read